Literature DB >> 10730547

Lidocaine patch 5%.

A M Comer1, H M Lamb.   

Abstract

Lidocaine patch 5% comprises a soft, stretchy adhesive patch (l0 by 14 cm) containing 5% lidocaine (700 mg) for the topical treatment of pain associated with postherpetic neuralgia (PHN). Lidocaine provides analgesic relief by blocking neuronal sodium channels. In clinical trials (conducted over 12 hours to 24 days) involving patients with allodynia associated with PHN, treatment with lidocaine patch 5% resulted in a significant reduction in pain intensity and increased pain relief compared with vehicle patch. Lidocaine patch 5% was associated with few adverse events, the most frequent being mild skin redness or irritation at the application site which occurred with a similar incidence with lidocaine and vehicle patch.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10730547     DOI: 10.2165/00003495-200059020-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  16 in total

Review 1.  The management of postherpetic neuralgia.

Authors:  D Bowsher
Journal:  Postgrad Med J       Date:  1997-10       Impact factor: 2.401

2.  Post-herpetic neuralgia: the relation of pain complaint, sensory disturbance, and skin temperature.

Authors:  Michael C Rowbotham; Howard L Fields
Journal:  Pain       Date:  1989-11       Impact factor: 6.961

3.  Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction.

Authors:  Marshall Devor; Patrick D Wall; Naor Catalan
Journal:  Pain       Date:  1992-02       Impact factor: 6.961

4.  A trial of intravenous lidocaine on the pain and allodynia of postherpetic neuralgia.

Authors:  A P Baranowski; J De Courcey; E Bonello
Journal:  J Pain Symptom Manage       Date:  1999-06       Impact factor: 3.612

5.  Topical lidocaine reduces pain in post-herpetic neuralgia.

Authors:  Michael C Rowbotham; Howard L Fields
Journal:  Pain       Date:  1989-09       Impact factor: 6.961

6.  Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study.

Authors:  B S Galer; M C Rowbotham; J Perander; E Friedman
Journal:  Pain       Date:  1999-04       Impact factor: 6.961

7.  Post-herpetic neuralgia: further post-mortem studies of cases with and without pain.

Authors:  C P N Watson; J H Deck; C Morshead; D Van der Kooy; R J Evans
Journal:  Pain       Date:  1991-02       Impact factor: 6.961

8.  The effect of intravenous lidocaine, tocainide, and mexiletine on spontaneously active fibers originating in rat sciatic neuromas.

Authors:  Charles Chabal; Lisa C Russell; Kim J Burchiel
Journal:  Pain       Date:  1989-09       Impact factor: 6.961

Review 9.  Clinical pharmacokinetics of lignocaine.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

10.  Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia.

Authors:  Michael C Rowbotham; Pamela S Davies; Christina Verkempinck; Bradley S Galer
Journal:  Pain       Date:  1996-04       Impact factor: 6.961

View more
  13 in total

Review 1.  WITHDRAWN: Topical lidocaine for the treatment of postherpetic neuralgia.

Authors:  Waqas Khaliq; Serena Alam; Naveen Kumar Puri
Journal:  Cochrane Database Syst Rev       Date:  2013-10-28

2.  Early experience with topical meloxicam and lidocaine combination for the treatment of vulvodynia.

Authors:  Rufina Kim; Kerri-Lynn Kelly; Merle Olson; J Curtis Nickel
Journal:  Can Urol Assoc J       Date:  2018-04-06       Impact factor: 1.862

Review 3.  Lidocaine/tetracaine medicated plaster: in minor dermatological and needle puncture procedures.

Authors:  Jamie D Croxtall
Journal:  Drugs       Date:  2010-11-12       Impact factor: 9.546

Review 4.  Perioperative pain management.

Authors:  Srinivas Pyati; Tong J Gan
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 5.  Inhibition of NaV1.7: the possibility of ideal analgesics.

Authors:  Yutaka Kitano; Tsuyoshi Shinozuka
Journal:  RSC Med Chem       Date:  2022-08-01

6.  Treatment of acute and chronic focal neuropathic pain in cancer patients with lidocaine 5 % patches. A radiation and oncology department experience.

Authors:  Escarlata López Ramírez
Journal:  Support Care Cancer       Date:  2012-12-15       Impact factor: 3.603

Review 7.  Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia.

Authors:  Pamela S Davies; Bradley S Galer
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Use of lidocaine patches for neuropathic pain in a comprehensive cancer centre.

Authors:  Julia Ann Fleming; Bradley David O'Connor
Journal:  Pain Res Manag       Date:  2009 Sep-Oct       Impact factor: 3.037

9.  Pre-emptive treatment of lidocaine attenuates neuropathic pain and reduces pain-related biochemical markers in the rat cuneate nucleus in median nerve chronic constriction injury model.

Authors:  Chi-Te Lin; Yi-Ju Tsai; Hsin-Ying Wang; Seu-Hwa Chen; Tzu-Yu Lin; June-Horng Lue
Journal:  Anesthesiol Res Pract       Date:  2011-11-24

10.  Post-herpetic neuralgia.

Authors:  Monica Tontodonati; Tamara Ursini; Ennio Polilli; Francesco Vadini; Francesco Di Masi; Damiano Volpone; Giustino Parruti
Journal:  Int J Gen Med       Date:  2012-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.